https://www.live-feeds.com/feed/why-viking-stock-jumped-on-obesity-data-novo-fallsContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/why-viking-stock-jumped-on-obesity-data-novo-fallshttps://www.live-feeds.com/feed/why-viking-stock-jumped-on-obesity-data-novo-falls#u83117Fri, 25 Sep 2026 00:01:26 +0000Viking Therapeutics shares jumped 36% after the company released positive data for its GLP-1/GIP dual agonist obesity drug. The candidate exceeded expectations in a small study, specifically regarding once-a-month maintenance dosing. While the data caused Viking stock to skyrocket, competitors Eli Lilly and Novo Nordisk saw their shares fall. However, Viking later faced a selloff after pricing an upsized financing deal at a 16% discount from Wednesday's closing price.Why it mattersThe obesity drug market is currently dominated by GLP-1 agonists from Novo Nordisk and Eli Lilly. Viking&#039